| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 35.4 | 30.4 | 0.0 |
| Other income | 0.1 | 0.2 | 0.6 |
| Total income | 35.5 | 30.6 | 0.6 |
| Profit before exceptional items & tax | 1.4 | 2.6 | 0.4 |
| Profit before tax | 1.4 | 2.6 | 0.4 |
| Net profit | 1.1 | 2.2 | 0.4 |
| Operating margin | 3.9% | 8.5% | 66.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +175.00% |
|---|---|
| Net profit, quarter on quarter | -50.00% |
BSE results filing, NSE: KABRADG. Figures extracted from the filing.
Kabra Drugs Ltd: key numbers
- Share price
- ₹18.76
- Market cap
- ₹44.48 Cr
- Revenue (annual)
- ₹92.74 Cr
- Net profit (annual)
- ₹4.96 Cr
- P/E (TTM)
- 5.9×Sector 50.4×
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kabra Drugs Ltd
All →Kabra Drugs Annual Report
Aanjaay Industries Ltd has submitted its Annual Report for FY 2025-2026 and issued notice for its 37th AGM scheduled for 30th September 2026.
Kabra Drugs Annual General Meeting
Aanjaay Industries Limited announced book closure dates from September 24th to September 30th, 2026, for its Annual General Meeting scheduled for September 30th, 2026.
Kabra Drugs Board Meeting Outcome
Aanjaay Industries Limited announced the notice for its 37th Annual General Meeting and approved board agenda items, including the appointment of directors and auditors.
Kabra Drugs Q1 FY27 Results: Turns Profitable, Net Profit ₹2.1 Cr
Kabra Drugs Ltd reported revenue from operations of ₹46.2 Cr (+541.7% YoY) and net profit of ₹2.1 Cr for Q1 FY27.
- Key figure
- Net profit ₹2.1 Cr